Standard

Obesity

GIPR · rs1800437

Where this position leads

Solid lines are connections this site curates. Dashed lines mean the two ends share a research paper — worth knowing, and not a claim that one explains the other.

What the study found

Who was studied 93,015 European ancestry overweight individuals, 32,858 European ancestry class I obese individuals, 9,889 European ancestry class II obese individuals, 2,896 European ancestry class III obese individuals, up to 65,840 European ancestry controls; replicated in 65,332 European ancestry overweight individuals, 22,373 European ancestry class I obese individuals, 5,476 European ancestry class II obese individuals, 1,162 European ancestry class III obese individuals, up to 39,294 European ancestry controls.

The effect Each copy of the G allele carried 1.10 times the odds of Obesity; p = 3 × 10⁻¹⁴.

How common The G allele had a frequency of about 78% in the people studied.

Where it sits Chromosome 19, band 19q13.32 — a missense change in GIPR.

What each result means

C/C No copy of the version the research linked to Obesity. This is the starting point the study compared everyone against.

C/G One copy of the version the research linked to Obesity. That is a smaller link than two copies.

G/G Two copies of the version the research linked to Obesity. That is the strongest link of the three results. A link in a study is not a diagnosis.

Source

Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture

Berndt SI, Gustafsson S, Mägi R, Ganna A, Wheeler E, Feitosa MF, Justice AE, Monda KL, Croteau-Chonka DC, Day FR, Esko T, Fall T

and 310 more — show all

Ferreira T, Gentilini D, Jackson AU, Luan J, Randall JC, Vedantam S, Willer CJ, Winkler TW, Wood AR, Workalemahu T, Hu YJ, Lee SH, Liang L, Lin DY, Min JL, Neale BM, Thorleifsson G, Yang J, Albrecht E, Amin N, Bragg-Gresham JL, Cadby G, den Heijer M, Eklund N, Fischer K, Goel A, Hottenga JJ, Huffman JE, Jarick I, Johansson Å, Johnson T, Kanoni S, Kleber ME, König IR, Kristiansson K, Kutalik Z, Lamina C, Lecoeur C, Li G, Mangino M, McArdle WL, Medina-Gomez C, Müller-Nurasyid M, Ngwa JS, Nolte IM, Paternoster L, Pechlivanis S, Perola M, Peters MJ, Preuss M, Rose LM, Shi J, Shungin D, Smith AV, Strawbridge RJ, Surakka I, Teumer A, Trip MD, Tyrer J, Van Vliet-Ostaptchouk JV, Vandenput L, Waite LL, Zhao JH, Absher D, Asselbergs FW, Atalay M, Attwood AP, Balmforth AJ, Basart H, Beilby J, Bonnycastle LL, Brambilla P, Bruinenberg M, Campbell H, Chasman DI, Chines PS, Collins FS, Connell JM, Cookson WO, de Faire U, de Vegt F, Dei M, Dimitriou M, Edkins S, Estrada K, Evans DM, Farrall M, Ferrario MM, Ferrières J, Franke L, Frau F, Gejman PV, Grallert H, Grönberg H, Gudnason V, Hall AS, Hall P, Hartikainen AL, Hayward C, Heard-Costa NL, Heath AC, Hebebrand J, Homuth G, Hu FB, Hunt SE, Hyppönen E, Iribarren C, Jacobs KB, Jansson JO, Jula A, Kähönen M, Kathiresan S, Kee F, Khaw KT, Kivimäki M, Koenig W, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Laitinen JH, Lakka TA, Langenberg C, Launer LJ, Lind L, Lindström J, Liu J, Liuzzi A, Lokki ML, Lorentzon M, Madden PA, Magnusson PK, Manunta P, Marek D, März W, Mateo Leach I, McKnight B, Medland SE, Mihailov E, Milani L, Montgomery GW, Mooser V, Mühleisen TW, Munroe PB, Musk AW, Narisu N, Navis G, Nicholson G, Nohr EA, Ong KK, Oostra BA, Palmer CN, Palotie A, Peden JF, Pedersen N, Peters A, Polasek O, Pouta A, Pramstaller PP, Prokopenko I, Pütter C, Radhakrishnan A, Raitakari O, Rendon A, Rivadeneira F, Rudan I, Saaristo TE, Sambrook JG, Sanders AR, Sanna S, Saramies J, Schipf S, Schreiber S, Schunkert H, Shin SY, Signorini S, Sinisalo J, Skrobek B, Soranzo N, Stančáková A, Stark K, Stephens JC, Stirrups K, Stolk RP, Stumvoll M, Swift AJ, Theodoraki EV, Thorand B, Tregouet DA, Tremoli E, Van der Klauw MM, van Meurs JB, Vermeulen SH, Viikari J, Virtamo J, Vitart V, Waeber G, Wang Z, Widén E, Wild SH, Willemsen G, Winkelmann BR, Witteman JC, Wolffenbuttel BH, Wong A, Wright AF, Zillikens MC, Amouyel P, Boehm BO, Boerwinkle E, Boomsma DI, Caulfield MJ, Chanock SJ, Cupples LA, Cusi D, Dedoussis GV, Erdmann J, Eriksson JG, Franks PW, Froguel P, Gieger C, Gyllensten U, Hamsten A, Harris TB, Hengstenberg C, Hicks AA, Hingorani A, Hinney A, Hofman A, Hovingh KG, Hveem K, Illig T, Jarvelin MR, Jöckel KH, Keinanen-Kiukaanniemi SM, Kiemeney LA, Kuh D, Laakso M, Lehtimäki T, Levinson DF, Martin NG, Metspalu A, Morris AD, Nieminen MS, Njølstad I, Ohlsson C, Oldehinkel AJ, Ouwehand WH, Palmer LJ, Penninx B, Power C, Province MA, Psaty BM, Qi L, Rauramaa R, Ridker PM, Ripatti S, Salomaa V, Samani NJ, Snieder H, Sørensen TI, Spector TD, Stefansson K, Tönjes A, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Vollenweider P, Wallaschofski H, Wareham NJ, Watkins H, Wichmann HE, Wilson JF, Abecasis GR, Assimes TL, Barroso I, Boehnke M, Borecki IB, Deloukas P, Fox CS, Frayling T, Groop LC, Haritunian T, Heid IM, Hunter D, Kaplan RC, Karpe F, Moffatt MF, Mohlke KL, O'Connell JR, Pawitan Y, Schadt EE, Schlessinger D, Steinthorsdottir V, Strachan DP, Thorsteinsdottir U, van Duijn CM, Visscher PM, Di Blasio AM, Hirschhorn JN, Lindgren CM, Morris AP, Meyre D, Scherag A, McCarthy MI, Speliotes EK, North KE, Loos RJ, Ingelsson E

Nature genetics · 2013 · PMID 23563607 · open access

What people read about alongside this

Blood sugar and insulin12 Heart and circulation3 Bones and fractures3 Brain and memory2 Kidneys1 Weight-loss medicines1 Caffeine and energy drinks1 Alcohol and the flush1

Papers in Europe PMC whose title or abstract names both this rsID and that subject. A shared paper means somebody wrote about the two together — it is not a claim that this position explains the subject.

In the news

2026-04-08 · 23andMe Research Institute, published in Nature (GWAS of 27,885 GLP-1 drug users)

Genetic predictors of GLP1 receptor agonist weight loss and side effects

A genome-wide study of 27,885 people taking GLP-1 drugs (semaglutide, tirzepatide) found a GLP1R variant linked to an extra 0.76 kg of weight loss per copy of the effect allele (P=2.9x10-10) -- direct genetic evidence the drug's own target gene shapes how well it works, not just a co-mention. The same study tied a GIPR variant (rs1800437, profiled on this site) to worse nausea and vomiting, specifically in people taking tirzepatide.

Questions about rs1800437

What is rs1800437?

rs1800437 is a single position in the genome, in or near the GIPR gene. Published research associates it with obesity. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs1800437 linked to?

On MyGeneLog this position is linked to Obesity and Body Weight. The research behind each link, and its sources, are set out on that condition page.

What do people read about alongside rs1800437?

Subjects that appear in the title or abstract of the same papers as this rsID include blood sugar and insulin (12 papers), heart and circulation (3 papers), bones and fractures (3 papers), brain and memory (2 papers), kidneys (1 papers). A shared paper means somebody wrote about the two together; it is not a claim that this position explains the topic.

Does having rs1800437 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs1800437 come from?

GWAS Catalog, Nat Genet 2013, PMID:23563607. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

Obesity (rs1800437). MyGeneLog™. https://www.mygenelog.com/variants/rs1800437

← See all variants